Xgeva去哪买的到呢？

Where can I buy it? On May 28, 2010, the European Commission approved Xgeva for the treatment of bone loss associated with hormone suppression in postmenopausal women with osteoporosis and prostate cancer. It can also be used in patients who are currently ineffective or intolerant to other treatments to reduce the risk of fractures. Xgeva was approved for the first time in 27 EU member states. In June of the same year, Xgeva was approved by the FDA for marketing. In May 2019, denosumab was conditionally approved for marketing in China, and patients can purchase it with a prescription in areas where it is listed.

It is understood that the Xgeva exported to Turkey by the American company Amgen is currently the one with the highest disease risk, and the price of 120mg is about $3,000. Due to different exchange rates, the price of Xgeva will also fluctuate. For specific price information, please consult the medical companion travel service. Since the Turkish version of Xgeva has not yet been launched in China and Xgeva is a prescription drug, patients can contact domestic overseas medical service agencies (such as Medical Companion Travel), who will translate the cases and deliver the medicine to the patient by direct mail. They will also provide guidance and answer questions for the patient during the medication.

It is a drug targeting the RANK ligand. Compared with the bisphosphonates that have been used clinically, Xgeva has the advantage of significantly prolonging the occurrence time of bone damage-related events. It can be administered subcutaneously and is easy to use. Clinical data shows that the drug does not require monitoring of renal function, while the use of bisphosphonates must be based on patient care. Renal function monitoring determines the speed of administration; however, Xgeva is currently relatively expensive, and its long-term efficacy and cost-effectiveness balance need to be further confirmed. It is expected that Xgeva, a specifically targeted RANK ligand inhibitor drug, can obtain more valuable research results in the treatment of solid tumors and bring new hope to patients with bone metastasis.